Inhibrx Biosciences, Inc. a clinical-stage biopharmaceutical company focused on developing therapeutics for oncology announced an update on the INBR...
300+ advanced CT scanners to be installed in public hospitals across 38 provinces by 2028, to support early diagnosis and treatment of non-communicab...
Affibody AB announced that the Trial Review Committee (TRC) has recommended to advance the Phase I clinical study with the Radioligand Therapy (RLT) cand...
Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO...
Johnson & Johnson announced the U.S. Food and Drug Administration (FDA) approved the supplemental New Drug Application (sNDA) for AKEEGA® (n...
Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, announced the EPO notified the...
Zydus Lifesciences Limited (including its subsidiaries and affiliates), an innovation-led life-sciences company, with an international presence...
Pillar Biosciences and AstraZeneca announced an expansion of their existing laboratory access program for NGS-based kitted liquid biopsy tumor profi...
Investigational T-cell engager, surovatamig, and CAR T-cell therapy, AZD0120, will show potential with initial data across multiple blood cancers New ...
Taiho Oncology Europe GmbH announced the UK launch of Lytgobi® (futibatinib), an irreversibly binding fibroblast growth factor receptor (FGFR) inhibi...
Clinical development of 212Pb-ADVC001 (ADVC001) is advancing rapidly with encouraging Phase 1b data presented at ESMO 2025 The Phase 2 expansion wil...
Imugene and JW Therapeutics (Shanghai) Co., LTD have entered a strategic collaboration to evaluate a novel combination therapy using Imugene's onCARlyt...
New name reflects company’s transformation as it advances toward the final phase of Lybrido™’s clinical development The Arletta but...
AstraZeneca’s IMFINZI® (durvalumab) in combination with standard-of-care FLOT chemotherapy (fluorouracil, leucovorin, oxaliplatin, and docetaxe...
© 2025 Biopharma Boardroom. All Rights Reserved.
